Recent vaccine development for human metapneumovirus

Ren, Junping; Phan, Thinh; Bao, Xiaoyong

doi:10.1099/vir.0.000083

Cited by 26 publications

(17 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This lineage-dependent genetic diversity should be also addressed in the near future to better understand the molecular dynamics of HMPV evolution. In addition to the relatively conserved F gene, which considered the best candidate vaccine antigen against HMPV infection [ 59 , 65 ], the genetically divergent characteristics of G genes across different genetic lineages may provide information that can be applied into the development of lineage-specific or multivalent HMPV vaccines and antivirals [ 11 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Genome-Wide Analysis of Human Metapneumovirus Evolution

et al. 2016

View full text Add to dashboard Cite

Human metapneumovirus (HMPV) has been described as an important etiologic agent of upper and lower respiratory tract infections, especially in young children and the elderly. Most of school-aged children might be introduced to HMPVs, and exacerbation with other viral or bacterial super-infection is common. However, our understanding of the molecular evolution of HMPVs remains limited. To address the comprehensive evolutionary dynamics of HMPVs, we report a genome-wide analysis of the eight genes (N, P, M, F, M2, SH, G, and L) using 103 complete genome sequences. Phylogenetic reconstruction revealed that the eight genes from one HMPV strain grouped into the same genetic group among the five distinct lineages (A1, A2a, A2b, B1, and B2). A few exceptions of phylogenetic incongruence might suggest past recombination events, and we detected possible recombination breakpoints in the F, SH, and G coding regions. The five genetic lineages of HMPVs shared quite remote common ancestors ranging more than 220 to 470 years of age with the most recent origins for the A2b sublineage. Purifying selection was common, but most protein genes except the F and M2-2 coding regions also appeared to experience episodic diversifying selection. Taken together, these suggest that the five lineages of HMPVs maintain their individual evolutionary dynamics and that recombination and selection forces might work on shaping the genetic diversity of HMPVs.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Based on the previous reports, HMPV infection appears to be seasonal [ 6 ], and co-infection with other respiratory pathogens is common [ 7 – 10 ]. However, there are still no vaccines or antivirals that can be used to treat HMPV infection [ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Genome-Wide Analysis of Human Metapneumovirus Evolution

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In 2013, a wild type recombinant HMPV having codon optimised SH protein was approved to be used as parent virus for the development of live attenuated HMPV specific vaccine candidate [ 100 ]. Recently, Ren et al discussed the significance of M2-2 protein based live attenuated vaccine candidate which can not only induce cellular immune response via the CTL epitope but also suppress HMPV induced host innate immunity and regulate the expression of miRNAs responsible for immune related gene expressions [ 29 , 82 , 84 , 85 ]. With these strategies under development, there is a need for the validation of an efficient vaccine candidate through clinical trials.…”

Section: Prophylactic Strategies For Hmpv Infectionmentioning

confidence: 99%

Prophylactic and therapeutic approaches for human metapneumovirus

Kumar

Srivastava

2018

VirusDis.

View full text Add to dashboard Cite

Human metapneumovirus (HMPV) is an important pneumovirus which causes acute respiratory disease in human beings. The viral infection leads to mild to severe respiratory symptoms depending on the age and immune status of the infected individual. Several groups across the world are working on the development of immunogens and therapy to manage HMPV infection with promising results under laboratory conditions but till date any virus specific vaccine or therapy has not been approved for clinical use. This minireview gives an overview of the prophylactic and therapeutic approaches to manage HMPV infections.

show abstract

“…At present, there is no hMPV‐ specific prophylactic vaccination strategy in place . Various vaccine candidates, such as the formalin‐ inactivated influenza viral protein‐based vaccines (viral hMPV‐F), recombinant and non‐recombinant live attenuated vaccines are under investigation . In order to facilitate an effective vaccine strategy, it is important to highlight the morbidity and mortality risks associated with hMPV in areas of highest ARI burden.…”

Section: Introductionmentioning

confidence: 99%

Human metapneumovirus in hospitalized children less than 5 years of age in Pakistan

Yousafzai

Ibrahim

Thobani

et al. 2018

Journal of Medical Virology

View full text Add to dashboard Cite

Acute respiratory infection (ARI) is the second leading cause of death in children less than 5 years of age worldwide. Human Metapneumovirus (hMPV) is associated with around 5-7% of the total pneumonia admissions in children. The aim of this study was to determine the magnitude of hMPV associated hospitalizations among children, in Karachi, Pakistan. A 3 years prospective study was conducted at the Aga Khan University Hospital (AKUH), from August 2009 to June 2012. Children less than 5 years of age, admitted with ARIs, were enrolled. Throat swabs were collected and tested for hMPV using real-time PCR. Multivariable log binomial regression analysis was performed. Out of 1150 children enrolled, hMPV was detected among 84/1150 (7%). About 87% of the enrolled children presented with cough, followed by fever (73%), nasal congestion (69%) and shortness of breath (68%). Of the hMPV positive subjects, most (56/84, 67%) were less than 12 months of age. The most common diagnosis in hMPV positive infants was pneumonia, followed by asthma and bronchiolitis. HMPV was identified year round, with peaks during February and August. Sore throat was found to be significantly associated with the hMPV infection (Adjusted RR 2.23; 95%CI 1.42-3.52). The proportion of hMPV was higher among hospitalized infants with ARI. Pneumonia was the primary discharge diagnoses of patients who tested positive for hMPV. hMPV could be a target for future vaccine to further decrease the burden of ARI morbidity and possibly mortality in developing countries.

show abstract

Recent vaccine development for human metapneumovirus

Cited by 26 publications

References 57 publications

Genome-Wide Analysis of Human Metapneumovirus Evolution

Genome-Wide Analysis of Human Metapneumovirus Evolution

Prophylactic and therapeutic approaches for human metapneumovirus

Human metapneumovirus in hospitalized children less than 5 years of age in Pakistan

Contact Info

Product

Resources

About